List of Excipients in Branded Drug PFIZERPEN

« Back to Dashboard

Generic Drugs Containing PFIZERPEN

Company	Ingredient	NDC	Excipient
Roerig	penicillin g potassium	0049-0420	CITRIC ACID MONOHYDRATE
Roerig	penicillin g potassium	0049-0420	SODIUM CITRATE
Roerig	penicillin g potassium	0049-0520	CITRIC ACID MONOHYDRATE

What are the Most Frequently-Used Excipients in PFIZERPEN?

# Of NDCs	Excipient
2	CITRIC ACID MONOHYDRATE
2	SODIUM CITRATE
1	SODIUM POLYMETAPHOSPHATE

Pfizerpen Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Pfizerpen is penicillin G potassium for injection, an established parenteral antibiotic marketed by Pfizer. Its commercial opportunity is not based on new-molecule exclusivity. It is based on improving reconstitution, stability, packaging, dosing convenience, supply reliability, and institutional workflow while preserving the product’s sterile injectable profile. The core excipient position is unusually limited: the labeled product is a powder for solution containing penicillin G potassium and no listed preservative or therapeutic excipient [1,2].

What drug is Pfizerpen and how is it administered?

Pfizerpen contains penicillin G potassium, also called benzylpenicillin potassium. It is supplied as a sterile powder for reconstitution and is administered by intravenous or intramuscular injection, depending on the clinical indication and dosing regimen [1].

Attribute	Pfizerpen
Active ingredient	Penicillin G potassium
Drug class	Natural penicillin, beta-lactam antibiotic
Dosage form	Sterile powder for injection
Routes	Intravenous and intramuscular administration
Manufacturer	Pfizer
Primary use	Serious infections caused by penicillin-susceptible organisms
Preservative status	No preservative listed in the product labeling
Potassium content	Approximately 2.8 mEq potassium per million units
Regulatory status	Established prescription injectable product
Primary competitive issue	Generic and institutional supply competition

The product is used for susceptible infections including certain streptococcal, pneumococcal, meningococcal, anaerobic, and spirochetal infections. The label requires dose selection based on organism susceptibility, infection site, severity, and patient factors [1].

The potassium load is a commercial and formulation constraint. High-dose intravenous therapy can produce a clinically relevant potassium exposure, particularly in patients with renal impairment, hyperkalemia risk, or substantial cumulative dosing. A sodium penicillin alternative may be preferred in some settings, although the choice depends on the clinical situation and available products.

What excipients are in Pfizerpen?

Pfizerpen’s commercial product is principally an active pharmaceutical ingredient powder rather than an excipient-rich formulation. The labeling identifies penicillin G potassium as the active component and does not identify a conventional preservative, bulking agent, surfactant, or stabilizer [1,2].

Current excipient profile

Formulation element	Pfizerpen position	Commercial implication
Active drug	Penicillin G potassium	Defines the reference composition
Preservative	None listed	Supports single-dose, preservative-free positioning
Buffer	None prominently identified in the labeled powder	Limits formulation complexity but creates reconstitution constraints
Surfactant	None listed	Low excipient burden and low risk of surfactant-related compatibility issues
Bulking agent	None listed	Product is not designed as a conventional excipient-supported lyophilized cake
Reconstitution fluid	Sterile diluent selected by institutional protocol and labeling	Opportunity for premixed or ready-to-use presentations
Container system	Sterile vial presentation	Opportunity for dual-chamber, pharmacy-ready, or flexible-container formats

The absence of listed excipients creates both an advantage and a limitation. It simplifies the inactive-ingredient profile and reduces the number of components that can create hypersensitivity, incompatibility, or extractables concerns. It also leaves fewer formulation tools for improving aqueous stability, concentration, visual clarity, or storage flexibility.

What excipient strategy is most attractive for penicillin G potassium?

The strongest strategy is to treat excipients as part of a broader delivery-system redesign rather than adding inactive ingredients to the existing vial.

1. Use a reconstitution-compatible buffer only if needed

Penicillin G is sensitive to degradation in aqueous solution, with stability affected by pH, temperature, concentration, and storage duration. A buffered formulation could improve solution stability, but the buffer must be compatible with intravenous administration, the intended concentration range, and the active beta-lactam.

Potential buffer systems could include phosphate or citrate families, subject to product-specific compatibility and stability testing. The risks include precipitation, altered degradation kinetics, changes in pH during storage, and incompatibility with common infusion fluids. Any new buffer would require a full pharmaceutical development package rather than a simple inactive-ingredient substitution.

2. Avoid unnecessary preservatives

A preservative would have limited value for a single-dose injectable product and could increase regulatory and clinical complexity. Preservatives may create toxicity concerns for neonates, infants, critically ill patients, or patients receiving repeated dosing. A preservative-free presentation is more compatible with hospital antimicrobial use and pediatric practice.

A multidose vial would create a stronger commercial rationale for antimicrobial preservation, but the operational and safety benefits would need to outweigh the higher formulation and labeling burden.

3. Develop a ready-to-use or pharmacy-ready presentation

The most commercially valuable improvement is likely a ready-to-use solution or a pharmacy-ready premix. Such a product could reduce:

• Reconstitution time
• Medication-preparation errors
• Nursing and pharmacy labor
• Exposure to vial manipulation
• Waste from partial-vial dosing
• Delays in emergency antibiotic administration

The primary technical barrier is aqueous stability over the intended shelf life. If a ready-to-use solution cannot achieve adequate stability, a dual-chamber system could separate the dry drug from the diluent until administration.

4. Consider a dual-chamber container

A dual-chamber vial, syringe, or flexible bag could maintain penicillin G potassium in the dry state while permitting on-demand reconstitution. This approach could preserve the stability benefits of the powder product while reducing manual preparation.

The commercial value would be highest in emergency departments, intensive-care units, operating rooms, neonatal units, and outpatient infusion settings. The container system would likely provide stronger protectable subject matter than a conventional excipient change.

5. Optimize concentration and potassium exposure

A reformulated product could target a concentration that reduces infusion volume or improves administration speed. The product must preserve dose accuracy and avoid excessive potassium delivery. Concentration changes can affect solubility, osmolality, infusion compatibility, and labeling.

A sodium penicillin product would address potassium concerns but would no longer be the same active pharmaceutical ingredient salt. A sodium-based product would compete directly with Pfizerpen while requiring separate development, regulatory, and manufacturing work.

What formulation patents could protect a Pfizerpen follow-on product?

The strongest patent opportunities would likely relate to the delivery system and manufacturing process rather than the basic penicillin G potassium molecule.

Potentially protectable subject matter

Patent target	Potential strength	Main limitation
Ready-to-use aqueous formulation	Moderate	Must show meaningful stability or clinical utility
Specific pH and buffer system	Low to moderate	Risk of obviousness and narrow claim scope
Dual-chamber container	Moderate to strong	Protection depends on device integration and claim drafting
Stable high-concentration solution	Moderate	Requires reproducible, unexpected stability data
Lyophilized cake with defined excipients	Moderate	May be difficult to distinguish from routine sterile-product practice
Reconstitution device	Moderate	Device claims may be easier to enforce than composition claims
Low-potassium alternative salt	Moderate	Competes as a different active ingredient presentation
Manufacturing process limiting degradation	Moderate	Requires robust process-performance evidence
Container closure and oxygen-control system	Low to moderate	Often vulnerable to obviousness challenges

A patent based only on adding a conventional buffer, sugar, or tonicity agent would face a material obviousness risk. A stronger position would combine a defined composition with an unexpected stability profile, a difficult concentration range, a specific container system, and clinically relevant preparation advantages.

The reference product’s long market history also creates prior-art risk. Published labels, compendial standards, older patents, hospital compounding literature, and historical penicillin formulations can narrow the available claim space.

When does Pfizerpen lose exclusivity?

Pfizerpen has no meaningful new-molecule exclusivity remaining. Penicillin G potassium has been used clinically for decades, and any original patent and regulatory exclusivity periods expired long ago.

The relevant commercial question is not when Pfizerpen loses exclusivity. It is whether a new product can obtain independent protection for:

• A differentiated formulation
• A delivery device
• A new dosage form
• A stability-enhancing manufacturing process
• A distinct clinical use
• A proprietary container or reconstitution system

An established injectable may remain commercially relevant after exclusivity expiration because hospitals value reliable supply, standardized preparation, and predictable procurement. Those factors do not create legal exclusivity, but they can support brand retention.

What is the Orange Book status of Pfizerpen?

The FDA Orange Book is the primary source for approved drug products, therapeutic-equivalence evaluations, and listed patents. Pfizerpen should be assessed through its current Drugs@FDA record and the Orange Book’s active and discontinued product data because injectable product status, marketing availability, and listing status can change over time [3,4].

For a follow-on sponsor, the key regulatory questions are:

1. Whether the intended product can be submitted as an abbreviated new drug application.
2. Whether the formulation and dosage form match the reference product closely enough for a 505(j) pathway.
3. Whether a different excipient system requires a 505(b)(2) application.
4. Whether Pfizerpen is the appropriate reference listed drug for the proposed strength and presentation.
5. Whether the product is currently marketed in the relevant presentation.

A product that changes the active salt, container architecture, route, concentration, or release profile may not fit comfortably within a standard ANDA. A 505(b)(2) route may be more appropriate where the sponsor relies partly on FDA findings for penicillin G potassium but introduces a material formulation or delivery change.

What generic entry risks exist for Pfizerpen?

Generic competition is structurally high because penicillin G potassium is an old, well-characterized active ingredient. The principal entry risks are operational rather than patent-based.

Generic and alternative-product risks

• Standard sterile powder vials may face price competition.
• Hospital systems may substitute based on contract pricing and supply continuity.
• Compounding pharmacies may prepare presentations during shortages, subject to applicable law.
• Alternative penicillin salts may compete where potassium exposure is undesirable.
• Other beta-lactams may displace penicillin G when broader coverage or dosing convenience is preferred.
• Premixed and ready-to-use antibiotics may gain preference despite higher unit pricing.

The highest-value differentiation is likely to come from reducing total treatment cost rather than lowering the vial price. A manufacturer that reduces preparation labor, discarded doses, infusion delays, and medication errors can justify a premium in institutional purchasing.

Which companies are challenging Pfizerpen commercially?

The competitive field includes generic injectable manufacturers, contract manufacturers, hospital suppliers, and companies selling alternative penicillin products. Publicly available data do not support a reliable conclusion that one specific company is conducting a current Paragraph IV challenge to Pfizerpen.

Because Pfizerpen has no meaningful new-molecule patent barrier, a Paragraph IV litigation strategy is less central than it would be for a recently approved branded product. The main competitive routes are likely to be:

• ANDA approval for an equivalent sterile powder injection
• 505(b)(2) approval for a differentiated presentation
• Contract manufacturing and hospital supply agreements
• Institutional substitution through group purchasing organizations
• Alternative penicillin or beta-lactam products

What manufacturing and intellectual-property barriers matter?

Sterile beta-lactam manufacturing creates meaningful technical and operational barriers even when patent barriers are weak.

Manufacturing constraints

Penicillin products require strict control of:

• Beta-lactam cross-contamination
• Dedicated or segregated manufacturing areas
• Environmental monitoring
• Sterility assurance
• Particulate control
• Container-closure integrity
• Powder uniformity
• Reconstitution performance
• Stability-indicating analytical methods

Beta-lactam sensitization risk makes facility segregation and cleaning validation commercially important. A manufacturer may need dedicated equipment or validated containment controls, increasing capital requirements and reducing the attractiveness of small-scale entry.

IP constraints

A follow-on sponsor should evaluate:

• Historical penicillin formulation patents
• Container and reconstitution-device patents
• Manufacturing-process patents
• Stability patents
• Hospital-use and preparation patents
• Trademark restrictions around Pfizerpen
• Trade-secret controls around filling and sterile processing

The basic active ingredient offers little defensible IP value. Device, process, and formulation claims offer the more realistic route to protection.

How does Pfizerpen compare with a differentiated follow-on product?

Factor	Pfizerpen powder vial	Ready-to-use follow-on	Dual-chamber follow-on
Formulation complexity	Low	High	Moderate to high
Reconstitution labor	High	Minimal	Low
Stability challenge	Lower before reconstitution	High	Moderate
Excipient burden	Low	Potentially higher	Potentially low
Hospital workflow benefit	Limited	High	High
Patent opportunity	Limited	Moderate	Moderate to strong
Regulatory complexity	Established	High	High
Manufacturing investment	Existing sterile powder capability	Aseptic liquid capability	Specialized container capability
Commercial premium potential	Low	Moderate	Moderate to high

What is the commercial opportunity for a Pfizerpen reformulation?

The best opportunity is a hospital-focused product that combines penicillin G potassium with simpler preparation and better supply reliability.

Priority opportunities

1. Ready-to-use intravenous presentation with validated refrigerated or room-temperature stability.
2. Dual-chamber vial or bag that enables rapid bedside reconstitution.
3. Pharmacy-ready concentrated solution designed for standardized dilution.
4. Unit-dose formats for neonatal and pediatric use.
5. Packaging that reduces vial waste for high-frequency dosing.
6. Supply agreements built around shortage prevention and guaranteed availability.
7. A potassium-conscious portfolio that includes sodium penicillin alternatives.

Revenue exposure is likely concentrated in institutional channels rather than retail pharmacy. Pricing depends on hospital contracts, group purchasing organization arrangements, shortage conditions, dose frequency, and the product’s ability to reduce preparation costs.

A premium product must demonstrate measurable workflow value. A modestly higher acquisition price can be commercially viable if the product reduces pharmacist preparation, nursing time, discarded medication, and urgent-dose delays.

Key Takeaways

• Pfizerpen is penicillin G potassium for injection, supplied primarily as a sterile powder for reconstitution.
• The labeled excipient profile is minimal, with no listed preservative or conventional stabilizer.
• The basic active ingredient and original product concept have little remaining patent value.
• The strongest commercial opportunities involve ready-to-use formulations, dual-chamber systems, reconstitution devices, and supply reliability.
• Excipient changes alone are unlikely to create a durable moat unless they produce unexpected stability or administration benefits.
• A reformulated product may require a 505(b)(2) pathway rather than a conventional ANDA.
• Beta-lactam segregation, sterile manufacturing, container closure, and supply continuity are more important barriers than molecule-level patent protection.
• Pfizerpen’s commercial value is concentrated in hospitals, emergency care, intensive care, pediatrics, and other settings requiring rapid parenteral antibiotic administration.

FAQs

Can a new excipient create patent protection around penicillin G potassium?

Yes, but only if the formulation produces a defensible technical result, such as unexpected stability, improved reconstitution, reduced degradation, or a clinically meaningful administration advantage. Routine use of a known buffer or tonicity agent would face substantial obviousness risk.

Is a ready-to-use Pfizerpen product commercially attractive?

Yes. A ready-to-use product could reduce pharmacy labor, preparation errors, vial waste, and administration delays. Its feasibility depends on achieving adequate solution stability and maintaining acceptable potassium exposure and compatibility.

Would a Pfizerpen reformulation qualify for an ANDA?

It might, if the formulation, dosage form, route, strength, and performance remain sufficiently equivalent to the reference product. A material excipient, concentration, container, or delivery-system change could require a 505(b)(2) application.

Can a manufacturer develop a preservative-containing multidose Pfizerpen vial?

Potentially, but the product would require justification for multidose use, preservative safety, antimicrobial effectiveness, container compatibility, and appropriate labeling. A single-dose preservative-free product is generally simpler for hospital and pediatric use.

What is the most defensible intellectual-property strategy for a Pfizerpen follow-on?

The strongest strategy would combine a differentiated container or reconstitution system with formulation and process claims supported by comparative stability data. A claim directed only to penicillin G potassium with a conventional excipient would be less durable.

References

1. Pfizer Inc. (n.d.). Pfizerpen: Penicillin G potassium for injection, USP prescribing information. U.S. Food and Drug Administration labeling repository.

2. National Library of Medicine. (n.d.). Pfizerpen- penicillin G potassium injection, powder, for solution. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/